share_log

Stephens & Co. Initiates Coverage On Cytek Biosciences With Overweight Rating, Announces Price Target of $9

Benzinga ·  Dec 14, 2023 05:46

Stephens & Co. analyst Mason Carrico initiates coverage on Cytek Biosciences (NASDAQ:CTKB) with a Overweight rating and announces Price Target of $9.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment